Zhejiang Starry PharmaceuticalLtd Past Earnings Performance
Past criteria checks 1/6
Zhejiang Starry PharmaceuticalLtd's earnings have been declining at an average annual rate of -20.9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 16.5% per year. Zhejiang Starry PharmaceuticalLtd's return on equity is 2.7%, and it has net margins of 2.1%.
Key information
-20.9%
Earnings growth rate
-21.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 16.5% |
| Return on equity | 2.7% |
| Net Margin | 2.1% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Zhejiang Starry PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,272 | 47 | 238 | 132 |
| 31 Dec 23 | 2,196 | 44 | 227 | 135 |
| 30 Sep 23 | 2,385 | -56 | 207 | 141 |
| 31 Mar 23 | 2,180 | -147 | 216 | 139 |
| 31 Dec 22 | 2,131 | -76 | 216 | 133 |
| 30 Sep 22 | 2,066 | 124 | 208 | 138 |
| 30 Jun 22 | 2,087 | 232 | 191 | 133 |
| 31 Mar 22 | 2,153 | 339 | 174 | 128 |
| 31 Dec 21 | 2,000 | 324 | 164 | 125 |
| 30 Sep 21 | 1,631 | 260 | 159 | 113 |
| 30 Jun 21 | 1,500 | 255 | 166 | 105 |
| 31 Mar 21 | 1,440 | 258 | 159 | 99 |
| 31 Dec 20 | 1,367 | 239 | 154 | 88 |
| 30 Sep 20 | 1,370 | 231 | 141 | 83 |
| 30 Jun 20 | 1,395 | 217 | 136 | 76 |
| 31 Mar 20 | 1,306 | 175 | 133 | 75 |
| 31 Dec 19 | 1,309 | 170 | 128 | 78 |
| 30 Sep 19 | 1,242 | 146 | 145 | 65 |
| 30 Jun 19 | 1,098 | 122 | 125 | 78 |
| 31 Mar 19 | 988 | 112 | 115 | 70 |
| 31 Dec 18 | 890 | 94 | 107 | 66 |
| 30 Sep 18 | 794 | 98 | 84 | 70 |
| 30 Jun 18 | 742 | 94 | 64 | 79 |
| 31 Mar 18 | 712 | 77 | 74 | 66 |
| 31 Dec 17 | 711 | 83 | 84 | 53 |
| 30 Sep 17 | 712 | 84 | 96 | 35 |
| 30 Jun 17 | 712 | 84 | 136 | 0 |
| 31 Mar 17 | 698 | 79 | 134 | 0 |
| 31 Dec 16 | 673 | 76 | 132 | 0 |
| 30 Sep 16 | 716 | 81 | 135 | 0 |
| 30 Jun 16 | 691 | 74 | 130 | 0 |
| 31 Mar 16 | 661 | 60 | 124 | 0 |
| 31 Dec 15 | 696 | 69 | 119 | 0 |
| 31 Dec 14 | 658 | 68 | 91 | 0 |
| 31 Dec 13 | 686 | 64 | 79 | 0 |
Quality Earnings: 603520 has a large one-off loss of CN¥44.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 603520 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603520's earnings have declined by 20.9% per year over the past 5 years.
Accelerating Growth: 603520 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 603520 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 603520's Return on Equity (2.7%) is considered low.